Sofgen Pharma S.A. (PROCF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sofgen Pharma S.A. (PROCF) trades at $0.0003 with AI Score 45/100 (Grade C). Procaps Group S. A. is a global pharmaceutical company specializing in the development and commercialization of a diverse range of medical solutions. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for PROCF: PROCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PROCF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PROCF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sofgen Pharma S.A. (PROCF) Healthcare & Pipeline Overview
Procaps Group S.A. (PROCF) excels in the pharmaceutical sector with a comprehensive portfolio of prescription drugs and OTC products, addressing multiple therapeutic areas and providing contract drug development services, positioning itself as a versatile player in the global healthcare market.
What Is the Investment Thesis for PROCF?
Procaps Group S.A. presents a compelling investment thesis driven by its diverse product portfolio and strong market position in the pharmaceutical industry. The company boasts a profit margin of 10.4% and a gross margin of 58.4%, indicating operational efficiency. Key growth catalysts include the expansion of its OTC product range and increasing demand for diabetes management solutions, projected to grow significantly in the coming years. Furthermore, Procaps' specialization as a CDMO provider positions it favorably against competitors, allowing for additional revenue streams. However, risks such as regulatory challenges and market competition must be carefully monitored. With a P/E ratio of 2.40, the company appears undervalued compared to industry peers, suggesting potential for future appreciation.
Based on FMP financials and quantitative analysis
PROCF Key Highlights
Market Cap of $0.06B reflects a niche position in the pharmaceutical market.
- P/E ratio of 2.40 indicates potential undervaluation compared to industry standards.
- Profit margin of 10.4% demonstrates effective cost management and operational efficiency.
- Gross margin of 58.4% exceeds industry averages, highlighting strong pricing power.
- Beta of 8.49 suggests high volatility, indicating potential risks in market fluctuations.
Who Are PROCF's Competitors?
PROCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PFE Pfizer Inc. | $27.82 | -1.50% | $159B | 67 |
| JNJ Johnson & Johnson | $267.37 | -2.21% | $644B | 90 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| ABBV AbbVie Inc. | $265.06 | -0.34% | $468B | 82 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PROCF's Key Strengths?
Diverse product portfolio covering various therapeutic areas.
- Strong operational efficiency with high gross and profit margins.
- Established presence in both prescription and OTC markets.
- Expertise in soft gelatin capsule technologies enhances product offerings.
What Are PROCF's Weaknesses?
Limited brand recognition compared to larger pharmaceutical companies.
- Dependence on a few key therapeutic areas for revenue generation.
- Exposure to regulatory risks in the pharmaceutical industry.
- No dividend yield may deter income-focused investors.
What Could Drive PROCF Stock Higher?
Expansion of OTC product offerings to capture a growing market segment.
- Development of diabetes management solutions to address rising healthcare demands.
- Strategic partnerships in contract drug development to enhance revenue streams.
- Investment in R&D for innovative drug development addressing unmet medical needs.
- Market expansion efforts in emerging markets to tap into increasing healthcare spending.
What Are the Key Risks for PROCF?
Financial-distress signal — its Altman Z-Score of 0.04 sits in the distress zone (elevated bankruptcy risk).
- Regulatory challenges could delay product approvals and market entry.
- Intense competition from larger pharmaceutical companies may impact market share.
- Market volatility affecting stock performance and investor sentiment.
- Risks associated with patent expirations and the emergence of generic competitors.
What Are the Growth Opportunities for PROCF?
- Diabetes Management Solutions: The global diabetes management market is expected to grow to $35 billion by 2026. Procaps' comprehensive solutions, including telemonitoring devices and oral anti-diabetic medications, position the company to capture a significant share of this expanding market.
- This segment allows Procaps to leverage its expertise in soft gelatin capsule technologies to attract partnerships with other pharmaceutical companies.
- International Market Expansion: Procaps is exploring opportunities to expand its footprint in emerging markets, particularly in Latin America and Asia, where healthcare spending is increasing. This strategic move aims to tap into the rising demand for pharmaceuticals and healthcare solutions in these regions.
- Innovative Drug Development: The company is investing in R&D to develop new therapeutic solutions, particularly in areas with unmet medical needs. This focus on innovation is expected to drive future growth and enhance Procaps' competitive edge in the pharmaceutical landscape.
What Are PROCF's Competitive Advantages?
- Strong brand recognition in various therapeutic areas enhances customer loyalty.
- Specialization in soft gelatin capsule technologies provides a competitive edge in product formulation.
- Established relationships with healthcare providers and institutions support consistent revenue streams.
- Diverse product portfolio mitigates risks associated with market fluctuations in specific segments.
What Does PROCF Do?
Procaps Group S.A., founded in 1977 and headquartered in Luxembourg City, is a prominent global pharmaceutical company engaged in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company has evolved significantly over the decades, establishing a strong presence in various therapeutic areas including women's health, pain relief, dermatological conditions, and more. Procaps offers a robust portfolio that includes branded prescription drugs and a wide array of over-the-counter (OTC) products spanning approximately eight therapeutic categories such as gastrointestinal health, skincare, cough and cold remedies, and pain management. Additionally, the company supplies pharmaceutical products for hospital use, including antibiotics, anticoagulants, and oncology treatments, showcasing its commitment to addressing critical healthcare needs. Procaps also provides comprehensive diabetes management solutions, which include blood glucose monitors and insulin delivery systems. As a contract drug development and manufacturing (CDMO) provider, Procaps specializes in soft gelatin capsule technologies, enhancing its competitive positioning in the pharmaceutical landscape. With a workforce of around 5,000 employees, Procaps continues to expand its market reach and innovate within the healthcare sector.
What Products and Services Does PROCF Offer?
- Develops and manufactures a diverse range of prescription drugs across various therapeutic areas.
- Offers a wide selection of over-the-counter (OTC) healthcare products.
- Provides pharmaceutical products for hospital use, including antibiotics and oncology treatments.
- Specializes in diabetes management solutions, including blood glucose monitors and insulin delivery systems.
- Operates as a contract drug development and manufacturing (CDMO) provider for other pharmaceutical companies.
- Utilizes advanced soft gelatin capsule technologies in its product offerings.
How Does PROCF Make Money?
- Generates revenue through the sale of prescription and OTC pharmaceutical products.
- Provides contract drug development services to other pharmaceutical companies.
- Offers specialized diabetes management solutions, contributing to diversified income streams.
- Engages in R&D to innovate and develop new therapeutic products.
- Utilizes its expertise in soft gelatin capsule technologies to enhance product offerings.
What Industry Does PROCF Operate In?
The pharmaceutical industry, particularly the specialty and generic drug manufacturing sector, is experiencing robust growth, driven by increasing healthcare demands and an aging population. Procaps Group S.A. is well-positioned within this landscape, leveraging its diverse product offerings and expertise in various therapeutic areas to compete effectively against established players. The competitive landscape includes both large multinational corporations and specialized firms, making innovation and regulatory compliance critical for success.
Who Are PROCF's Key Customers?
- Healthcare providers and hospitals seeking pharmaceutical products.
- Consumers purchasing over-the-counter healthcare solutions.
- Pharmaceutical companies requiring contract development and manufacturing services.
- Patients managing chronic conditions, particularly diabetes.
- Retail pharmacies and distributors for OTC product sales.
Company Profile
Sofgen Pharma S.A. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Luxembourg City, LU. The company is led by CEO Melissa Angelini. PROCF has traded publicly since 2021.
How Sofgen Pharma S.A. Is Valued
Relative to its peer group, PROCF's quantitative score of 45/100 is below the peer average of 81/100.
Key Financial Metrics
Return on assets is 9.2%, showing how much profit it generates from its asset base. PROCF trades at a trailing price-to-earnings ratio of 2.40, below the Healthcare sector average of ~23x. Its free cash flow yield is -17.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 41.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Sofgen Pharma S.A.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.04 places it in the distress zone, a signal of elevated financial risk.
PROCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Sofgen Pharma's recent insider buying could signal strong confidence in the company's future prospects, suggesting they believe the stock is undervalued.
- The social trading community seems to be buzzing with positive discussions around PROCF, indicating growing optimism and potential for increased demand.
- Recent developments in the pharmaceutical sector may be creating a favorable environment for companies like Sofgen Pharma, boosting investor sentiment.
- There's a perception that PROCF is undervalued compared to its peers, attracting attention from value investors looking for overlooked opportunities.
Bear Case
- Despite positive sentiment, some community members are expressing concerns about the long-term viability of Sofgen's pipeline.
- Recent market volatility and broader economic uncertainty could negatively impact smaller pharmaceutical companies like PROCF.
- There's a perception that Sofgen Pharma lacks the resources to effectively compete with larger, more established players in the industry.
- Some analysts are questioning the sustainability of the current positive momentum, suggesting it may be driven by short-term speculation rather than solid fundamentals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PROCF Latest News
No recent news available for PROCF.
PROCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PROCF.
Price Targets
Wall Street price target analysis for PROCF.
PROCF MoonshotScore
What does this score mean?
The MoonshotScore rates PROCF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Melissa Angelini
CEO
Melissa Angelini has a robust background in the pharmaceutical industry, with over 20 years of experience in various leadership roles. She holds a degree in Pharmacy and an MBA, equipping her with both technical and business acumen. Prior to her role at Procaps, she held significant positions at leading pharmaceutical firms, driving growth and innovation.
Track Record: Under Melissa's leadership, Procaps has expanded its product offerings and enhanced its market presence, focusing on innovation and operational efficiency. She has been instrumental in navigating regulatory challenges and fostering strategic partnerships.
PROCF OTC Market Information
The OTC Other tier represents stocks that trade over-the-counter but do not meet the requirements for the more regulated exchanges like NYSE or NASDAQ. Companies in this tier may have less stringent reporting requirements, leading to potential information asymmetry for investors.
- OTC Tier: OTC Other
- Limited regulatory oversight may increase the risk of fraud or mismanagement.
- Lower trading volumes can lead to higher volatility and price fluctuations.
- Potential lack of transparency in financial reporting and disclosures.
- Increased susceptibility to market manipulation due to lower liquidity.
- Verify the company's financial health through available reports.
- Assess the management team's track record and experience.
- Examine the competitive landscape and market positioning.
- Monitor regulatory developments affecting the pharmaceutical sector.
- Review product pipeline and upcoming clinical trials.
- Established history since 1977 indicates a long-term presence in the industry.
- Diverse product portfolio across multiple therapeutic areas.
- Recognition as a CDMO provider showcases industry credibility.
- Engagement in R&D activities demonstrates commitment to innovation.
PROCF Healthcare Stock FAQ
What does the AI Score mean for PROCF?
PROCF holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Procaps Group S.A. is a global pharmaceutical company specializing in the development and commercialization of a diverse range of medical solutions. Founded in 1977, the company operates in various …
What does Procaps Group S.A. do?
Procaps Group S.A. engages in the development, manufacturing, and commercialization of a diverse range of medical solutions. The company offers both branded prescription drugs and over-the-counter (OTC) products across various therapeutic areas, including women's health, pain relief, and diabetes management. Additionally, Procaps provides pharmaceutical products for hospital use and operates as a contract drug development and manufacturing provider.
What do analysts say about PROCF stock?
Analysts generally view Procaps Group S.A. as a company with potential for growth due to its diverse product offerings and strong market position. The company's P/E ratio of 2.40 is considered low compared to industry averages, suggesting potential undervaluation. Analysts highlight the importance of monitoring the company's expansion efforts and product pipeline for future growth opportunities.
What are the main risks for PROCF?
Procaps Group S.A. faces several risks inherent in the pharmaceutical industry, including regulatory challenges that could affect product approvals and market entry. Intense competition from larger pharmaceutical companies poses a threat to market share, while market volatility may impact stock performance. Additionally, the company must navigate risks associated with patent expirations, which could lead to increased competition from generic drugs.
What are the key factors to evaluate for PROCF?
Sofgen Pharma S.A. (PROCF) holds an AI score of 45/100 (low). Procaps Group S.A. presents a compelling investment thesis driven by its diverse product portfolio and strong market position in the pharmaceutical industry. Not financial advice.
How frequently does PROCF data refresh on this page?
PROCF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PROCF's recent stock price performance?
Sofgen Pharma S.A. (PROCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio covering various therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PROCF overvalued or undervalued right now?
Sofgen Pharma S.A. (PROCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PROCF before investing?
Before investing in Sofgen Pharma S.A. (PROCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information and may be subject to change.